Young Kwang Chae, Professor of Medicine at Northwestern University, shared on X:
“Excited to see the phase 3 HERON-Lung01 trial results presented at ESMO 2026 by Dr. Chong-Rui Xu (lead author Prof. Yi-Long Wu)!
Ruzaltatug rozetecan (SHR-A2009) – a novel HER3-directed ADC – shows significant PFS improvement vs platinum-based chemo in EGFRm NSCLC after TKI progression:
Key Highlights:
- mPFS: 8.3 mo vs 5.4 mo (HR 0.47 [95% CI 0.36-0.60], p < 0.0001)
- ORR: 60.0% vs 34.3%
- OS Trend: Favors ruzaltatug rezetecan (HR 0.70) despite chemo crossover
- Safety: Differentiated & manageable safety profile with low ILD rates (2.4%)
Positioning ruzaltatug rezetecan as a strong potential new standard of care in EGFR-TKI resistant NSCLC!”
You can also read: Risvutatug Rezetecan Meets Overall Survival Endpoint in Phase III SCLC Trial in China
